Krystal Biotech Inc
(NAS:KRYS)
$
195.64
-3.15 (-1.58%)
Market Cap: 5.62 Bil
Enterprise Value: 5.16 Bil
PE Ratio: 54.31
PB Ratio: 6.80
GF Score: 40/100 
Krystal Biotech Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 15, 2022 / 05:40PM GMT
Release Date Price:
$53.34
(+5.71%)
Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst
All right. So thanks, everyone, for joining us this morning at the Goldman Sachs Global Healthcare Conference. Really pleased to be joined by Krish from Krystal Biotech to give us an update on where things are, where things are headed. Obviously, it's a really important year for the company. And so thanks for joining us, Krish.
Krish S. Krishnan
Krystal Biotech, Inc. - Founder, Chairman, President & CEO
Thanks for having me.
Questions & Answers
Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst
Great. So let's start with the discussion of your lead drug VYJUVEK for dystrophic epidermolysis bullosa, or DEB. So first level, let's start with the kind of straightforward high-level discussion of the mechanism of action of VYJUVEK.
Krish S. Krishnan
Krystal Biotech, Inc. - Founder, Chairman, President & CEO
So yes, so VYJUVEK is a modified
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers